FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same…
Recent Articles
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
FAST NEWS: Legend Biotech shares jump on rising cancer drug sales
LEGN.US
-
FAST NEWS: Hillhouse invests $22 million in Legend Biotech
LEGN.US
-
FAST NEWS: Legend Biotech to raise $300 million from share sale
LEGN.US 1548.HK
-
FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
1548.HK LEGN.US
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
Discover hidden China stock gems in our weekly newsletter